ASP Isotopes Inc. is a development stage advanced materials company. The Company is engaged in the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process (ASP technology). Its initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. Its Nuclear Fuels segment is focused on research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment is focused on research and development of technologies and methods used to separate high-value, low-volume isotopes (such as C-14, Mo-100, and Si-28) for highly specialized target end markets other than advanced nuclear fuels, including pharmaceuticals and agrochemicals, nuclear medical imaging, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 5407.52% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 23.85M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 23.85M.
Overvalued
The company’s latest PE is -2.75, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 73.95M shares, increasing 13.33% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 18.33K shares of this stock.